Five ALK tyrosine kinase inhibitors (TKIs) are approved in the US for the treatment of patients with advanced NSCLC harboring ALK fusions: crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib.148,149 Crizotinib is the only FDA-approved therapy for advanced/unresectable ALK-fusion positive inflammatory myofibroblastic tumors.150. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.